Latest From CSL Ltd.
India's Glenmark gets US Complete Response Letter for Ryaltris but emphasizes the FDA hasn’t faulted the clinical data for the product, and that the action won’t impact recent alliances for the rhinitis asset.
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.
The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Commonwealth Serum Laboratories
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
- Paul Perreault, CEO & Mng. Dir.
- Contact Info
Phone: (61) 3 9389 1911
45 Poplar Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.